Pharmaceutical - Rituxan

Filter

Current filters:

Rituxan

Popular Filters

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

07-11-2013

Swiss drug major Roche (ROG: SIX) has announced new data from the second stage of the CLL11 Phase III…

EuropeGazyvaMabTheraOncologyPharmaceuticalResearchRituxanRoche

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia

04-02-2013

Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational…

BiotechnologyGA101MabTheraobinutuzumabOncologyPharmaceuticalResearchRituxanRoche

Company Spotlight

ImmunoGen

ImmunoGen

Back to top